What is the average price target for VERADIGM INC (MDRX) stock?
12 analysts have analysed MDRX and the average price target is 13.99 USD. This implies a price increase of 105.41% is expected in the next year compared to the current price of 6.81.
VERADIGM INC (MDRX) Forecast, Price Target & Analyst Ratings
NASDAQ:MDRX • US01988P1084
Current stock price
6.81 USD
-0.79 (-10.39%)
At close:
6.86 USD
+0.05 (+0.73%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERADIGM INC (MDRX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- $0.31
- Revenue Estimate
- 169.77M
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.99
Upside
+ 105.41%
From current price of $6.81 to mean target of $13.99, Based on 12 analyst forecasts
Low
$10.10
Median
$11.22
High
$27.30
Price Target Revisions
1 Month
-2.86%
3 Months
-5.56%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for MDRX. The average price target is 13.99 USD. This implies a price increase of 105.41% is expected in the next year compared to the current price of 6.81.
The average price target has been revised downward by 5.56% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.67%
MDRX was analyzed by 12 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about MDRX.
In the previous month the buy percentage consensus was at a similar level.
MDRX was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-01-31 | Stephens & Co. | Maintains | Equal-Weight -> Equal-Weight |
| 2024-05-28 | TD Cowen | Maintains | Buy -> Buy |
| 2024-03-19 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2024-01-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-01-03 | Barclays | Initiate | Equal-Weight |
| 2023-11-14 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-10-10 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-07-06 | Argus Research | Downgrade | Buy -> Hold |
| 2023-04-12 | Stephens & Co. | Initiate | Equal-Weight |
| 2023-02-01 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-12-07 | Argus Research | Upgrade | Hold -> Buy |
| 2022-11-18 | JP Morgan | Maintains | Underweight |
| 2022-11-09 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2022-09-16 | Keybanc | Initiate | Sector Weight |
| 2022-07-12 | Goldman Sachs | Initiate | Neutral |
| 2022-06-10 | Piper Sandler | Maintains | Neutral |
| 2022-05-06 | Piper Sandler | Maintains | Neutral |
| 2022-03-04 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2022-03-03 | SVB Leerink | Maintains | Outperform |
| 2022-01-25 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2021-11-23 | Deutsche Bank | Maintains | Hold |
| 2021-08-06 | RBC Capital | Maintains | Outperform |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-05-26 | SVB Leerink | Maintains | Market Perform |
| 2021-04-30 | SVB Leerink | Maintains | Market Perform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- $0.31
- Revenue Estimate
- 169.77M
- Revenue Q2Q
- -56.66%
- EPS Q2Q
- -61.08%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
99,897.10%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
The next earnings revenue estimate has been revised upward by 99897.1% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.633B 0.91% | 1.503B -7.96% | 1.503B 0.02% | 626.58M -58.31% | 645.85M 3.08% | 680.44M 5.36% | 781.52M 14.86% | 822.17M 5.20% | |
| EBITDA YoY % growth | 144M 50.63% | 136.3M -5.35% | 265.1M 94.50% | 171.31M -35.38% | 138.03M -19.43% | 148.67M 7.71% | 261.53M 75.91% | 280.6M 7.29% | |
| EBIT YoY % growth | -63.1M 34.75% | -56M 11.25% | 89M 258.93% | 120.6M 35.51% | 90.712M -24.78% | 100.02M 10.26% | 222.05M 122.01% | 241.03M 8.55% | |
| Operating Margin | -3.87% | -3.73% | 5.92% | 19.25% | 14.05% | 14.70% | 28.41% | 29.32% | |
| EPS YoY % growth | 0.67 -6.94% | 0.76 13.43% | 1.48 94.74% | 0.83 -44.00% | 0.96 16.31% | 1.02 5.82% | 1.19 16.61% | 0.55 -53.47% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.31 -61.08% | 0.30 130.15% | 0.22 23.72% | 0.28 21.51% | 0.33 8.81% | 0.70 132.96% | 0.27 20.61% | 0.31 10.70% | 0.35 5.69% | 1.82 160.49% | 0.40 48.10% | 0.48 54.95% |
| Revenue Q2Q % growth | 169.77M -56.66% | 151.41M 6.10% | 158.88M 5.29% | 162.81M 7.18% | 173.83M 2.39% | 154.99M 2.36% | 164.09M 3.28% | 167.87M 3.11% | 179.01M 2.98% | 176.05M 13.59% | 189.01M 15.19% | 196.45M 17.03% |
| EBITDA Q2Q % growth | 54.222M -75.07% | 33.482M 61.75% | 34.408M 47.67% | 36.346M -45.99% | 41.514M -23.44% | 32.266M -3.63% | 35.53M 3.26% | 37.502M 3.18% | 43.282M 4.26% | 23.97M -25.71% | 31.212M -12.15% | 36.72M -2.09% |
| EBIT Q2Q % growth | 43.196M 4.34% | 20.06M 203.94% | 18.003M 446.21% | 21.318M -14.73% | 27.438M -36.48% | 17.034M -15.08% | 20.842M 15.77% | 25.568M 19.94% | 28.152M 2.60% | 21.216M 24.55% | 28.254M 35.56% | 33.66M 31.65% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VERADIGM INC / MDRX Forecast FAQ
What are the consensus estimates for MDRX stock next earnings?
The consensus EPS estimate for the next earnings of VERADIGM INC (MDRX) is 0.31 USD and the consensus revenue estimate is 169.77M USD.
How do analysts rate VERADIGM INC (MDRX)?
The consensus rating for VERADIGM INC (MDRX) is 76.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.